New york: AstraZeneca has announced a US$50 billion investment in the United States by 2030, building on America’s global leadership in medicines manufacturing and RandD. This significant investment is anticipated to create tens of thousands of new, highly skilled direct and indirect jobs across the nation, thereby driving growth and delivering next-generation medicines for patients both in America and worldwide.

According to Emirates News Agency, the cornerstone of this landmark investment is a new multi-billion-dollar US manufacturing facility. This facility will produce drug substances for AstraZeneca’s innovative weight management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9, and combination small molecule products. The new state-of-the-art center will produce small molecules, peptides, and oligonucleotides.

This multi-billion dollar capital investment supplements the $3.5 billion announced in November 2024. The drug substance facility, planned to be in the Commonwealth of Virginia, would be AstraZeneca’s largest single manufacturing investment globally. The facility will utilize AI, automation, and data analytics to optimize production.

The $50 billion investment across AstraZeneca’s RandD and manufacturing footprint in the US over the next five years also includes expanding the RandD facility in Gaithersburg, Maryland; building a state-of-the-art RandD center in Kendall Square, Cambridge, Massachusetts; establishing manufacturing facilities for cell therapy in Rockville, Maryland and Tarzana, California; continuing manufacturing expansion in Mount Vernon, Indiana; and expanding the specialty manufacturing in Coppell, Texas.